Dear Medicines and Healthcare Products Regulatory Agency,

In September 2016 the MHRA made a move to define CBD as a purely medicinal compound, which was only stopped after public intervention.

It is however known that the MHRA to this day reserve the right to define CBD as a medicinal compound.

What's also known is that GW Pharmaceuticals was the only company in the UK who would benefit from such a move, and that they had completed Phase III trials on Epidiolex barely 3 months before the MHRA tried to define CBD as a purely medicinal compound in 2016.

Subsequently, I would like to request all information and communications between GW Pharmaceuticals from 01/01/2012 to 01/01/2017 that discuss cannabis, cannabinoids and cannabidiol.

I would also like to request the same information and communications between Deloitte and the MHRA, as it's come to my attention that they may have been managing the private equity side of an agreement, most likely a Public-Private Partnership, between GW and the British Government

Yours faithfully,

Cefyn Jones

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Our Ref: FOI 23/911

Dear Cefyn Jones,

RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000

Thank you for your enquiry which we received on 24 November.

I confirm that your request is now being handled under the Freedom of Information Act and you should receive a reply within 20 working days from our date of receipt.

If you need to contact us again about this request, please quote the reference number above.

Please be aware that we publish FOIs replies and these are redacted and are located on our website at the following link below.
https://www.gov.uk/government/collection...

Kind Regards,

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf,
London E14 4PU
Telephone 020 3080 6000

show quoted sections

FOILicensing, Medicines and Healthcare Products Regulatory Agency

Dear Cefyn Jones,

Thank you for your email. We would like to clarify parts of your request before starting to process it.

You have mentioned "I would like to request all information and communications between GW Pharmaceuticals" was the intention to include between GW pharmaceuticals and presumably MHRA? In addition, you mention 'all information and communications [...] that discuss cannabis, cannabinoids and cannabidiol'. However, the word 'discuss' is a broad and non-specific term, for example, we hold information in relation to the regulatory dossier/procedure for Sativex but we feel that this is unlikely to align with the purpose of your request? As part of advice and assistance, we would also mention that the acronyms CBD and/or THC is not listed as a search term would you like these terms to also be included.

We trust that you will find this clarification useful, however, if you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask us to review our actions and decisions by writing to: [MHRA request email], and requesting an internal review.

Please note that your internal review request must be in a recordable format (email, letter, audio tape etc.), and that you have 40 working days upon receipt of this letter to ask for a review. We aim to provide a full response to your review request within 20 working days of its receipt. Please quote
the reference number above in any future communications.

If you are not content with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a
decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted online via an electronic form: https://ico.org.uk/make-a-complaint/foi-...

Or in writing to:
Information Commissioner's Office,
Wycliffe House,
Water Lane,
Wilmslow,
Cheshire,
SK9 5AF

Yours sincerely,

HQA FOI Team

show quoted sections

Dear FOILicensing,

My apologies for the delay in response.

I am happy to make this a fresh FOI request should the need arise.

I do realise that this is a tricky FOI request so I will narrow it down as much as possible.

I'm looking for all files and information that you hold regarding GW Pharmaceuticals between 1997-2000.

The reason for this request is that the Home Office granted GW a license to grow in Jun 1998 to create medicinal cannabis/cannabinoid based products.

I am aware that GW recieved an R&D license in 2001, and that this would have involved some level of collaboration with the Home Office.

I'm also aware that the MHRA didn't 'exist' between 1997-2000, however, I do believe that there was a change of name, but not a change in department or responsibilities

Yours sincerely,

Cefyn Jones

Business Support Team, Medicines and Healthcare Products Regulatory Agency

MHRA reference: FOI2024/00023

Dear Cefyn Jones,

Thank you for your information request, which we received on 4 April. We
have understood your request to be for the following information:

I'm looking for all files and information that you hold regarding GW
Pharmaceuticals between 1997-2000.

If we have misunderstood or misinterpreted your request, please contact us
as soon as possible.

We will deal with your request under the Freedom of Information Act 2000
(FOIA). The statutory time frame for response is 20 working days; this
begins on the first working day after receipt, and we will respond by 2
May 2024.

If you need to contact us about this request, please quote the reference
number above.

We publish our responses to FOI requests with requester details removed.
You can view these on our website here:

[1]Transparency and freedom of information releases - GOV.UK (www.gov.uk)

Yours sincerely

Healthcare, Quality and Access Group

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

[2]gov.uk/mhra

[3]Stay connected

For information on how the Agency uses your personal data and your data
protection rights, please see our three centres' Privacy Notices: [4]MHRA,
[5]CPRD and [6]NIBSC.

References

Visible links
1. https://eur01.safelinks.protection.outlo...
2. https://eur01.safelinks.protection.outlo...
3. https://eur01.safelinks.protection.outlo...
4. https://eur01.safelinks.protection.outlo...
5. https://eur01.safelinks.protection.outlo...
6. https://eur01.safelinks.protection.outlo...

Business Support Team, Medicines and Healthcare Products Regulatory Agency

1 Attachment

Dear Cefyn Jones,

I am writing in response to your request for information, received 4th
April.

Please find the response to your request attached.

Yours sincerely,

Healthcare, Quality and Access Group

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

[1]gov.uk/mhra

[2]Stay connected

For information on how the Agency uses your personal data and your data
protection rights, please see our three centres' Privacy Notices: [3]MHRA,
[4]CPRD and [5]NIBSC.

References

Visible links
1. https://eur01.safelinks.protection.outlo...
2. https://eur01.safelinks.protection.outlo...
3. https://eur01.safelinks.protection.outlo...
4. https://eur01.safelinks.protection.outlo...
5. https://eur01.safelinks.protection.outlo...